Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.8650
Nov 19 • 3:58 PM ET Dollar change-0.0070 Percentage change(-0.80%)
Aftermarket Close
0.8650
Aftermarket • 5:00 PM ET Dollar change0.0000 Percentage change(0.00%)
Nov 18, 8:25 AMAllarity Therapeutics says it received a U.S. patent covering stenoparib dosing regimens, with protection extending into 2045.
Index
-
Market Cap
13.84M
Enterprise Value
12.77M
Income
-15.73M
Sales
0.35M
Book/sh
-0.14
Cash/sh
1.51
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
8
IPO
Dec 21, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
39.54
P/B
-
P/C
0.57
P/FCF
-
EV/EBITDA
-
EV/Sales
36.48
Quick Ratio
0.91
Current Ratio
0.91
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-0.98
EPS next Y
-0.87
EPS next Q
0.01
EPS this Y
2.56%
EPS next Y
-14.47%
EPS next 5Y
-
EPS past 3/5Y
99.25% 94.60%
Sales past 3/5Y
- -
EPS Y/Y TTM
38.64%
Sales Y/Y TTM
-
EPS Q/Q
-104.31%
Sales Q/Q
-
Insider Own
5.35%
Insider Trans
0.00%
Inst Own
6.83%
Inst Trans
2.83%
ROA
-65.51%
ROE
-322.66%
ROIC
-
Gross Margin
86.29%
Oper. Margin
-3938.29%
Profit Margin
-4493.71%
SMA20
-7.23%
SMA50
-11.60%
SMA200
-28.36%
Trades
Shs Outstand
16.15M
Shs Float
15.14M
52W High
1.84 -52.98%
52W Low
0.77 12.53%
Volatility
10.99% 9.70%
ATR (14)
0.09
RSI (14)
42.91
Beta
0.49
Rel Volume
1.09
Avg Volume
128.19K
Volume
139,604
Perf Week
-5.34%
Perf Month
-1.66%
Perf Quarter
-39.08%
Perf Half Y
-47.89%
Perf YTD
-19.91%
Perf Year
-19.16%
Perf 3Y
-99.72%
Perf 5Y
-
Perf 10Y
-
Prev Close
0.87
Price
0.87
Change %
-0.80%
Consensus
Strong Buy
Avg. Price Target
$11.25
Implied Upside
+1,200.6%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 28, 2025Initiated
AAscendiant Capital Markets
Buy$9+940.5%
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The company is focused on development of stenoparib, a novel PARP and tankyrase inhibitor for advanced ovarian cancer patients, using its DRP technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity Therapeutics was founded by Steen Knudsen and Thomas H. Jensen in 2004 and is headquartered in Tarpon Springs, FL.
FounderMr. Thomas H. Jensen
President & Chief Development OfficerDr. Jeremy R. Graff Ph.D.
Founder & Chief Scientific OfficerDr. Steen Meier Knudsen Ph.D.
Chief Financial OfficerMr. Jeffrey S. Ervin M.B.A.
Consultant Chief Medical OfficerDr. Jose L. Iglesias M.D.